Tag Archives: Dan Loeb Urges Amgen To Break Up

Third Point’s Dan Loeb Pushes Amgen Breakup

Speculation began almost immediately after Dan Loeb’s Third Point impressively raised $2.5b in just two weeks this summer. Who would the new targets be? Existing investments? Foreign companies? One new mark was just identified in the fund’s most recent quarterly letter as Amgen (AMGN), the $100b+ market cap biotech giant. The letter, which is worth a read in its entirety, suggests that… Read More »